Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes

Gene

Volumn 523, Issue 1, 2013, Pages 20-26

  Yilmaz Aydogan, Hulya ^a   Kurnaz, Ozlem ^a   Kucukhuseyin, Ozlem ^a   Akadam Teker, Basak ^a   Kurt, Ozlem ^a   Eronat, Allison Pinar ^a   Tekeli, Atike ^b   Bugra, Zehra ^c   Ozturk, Oguz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

APOE; Coronary heart disease; PPARA; PPARG; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; APOLIPOPROTEIN E4; CASE-CONTROL STUDIES; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; PPAR GAMMA; RISK FACTORS; TURKEY;

EID: 84877800824     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.136     Document Type: Article

References (30)

1. Beaven S.W., Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 2006, 57:313-329.
2. Bennet A.M., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298(11):1300-1311.
3. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8(1):1-21.
4. Do H.Q., et al. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor α, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism 2009, 58(3):283-289.
5. Flavell D.M., et al. Variation in the PPARa gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 2000, 43:673-680.
6. Flavell D.M., et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002, 105(12):1440-1445.
7. Foucher C., et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 2004, 14(12):823-829.
8. Garenc C., et al. Population prevalence of APOE, APOC3 and PPAR-a mutations associated to hypertriglyceridemia in French Canadians. J. Hum. Genet. 2004, 49(12):691-700.
9. Gouni-Berthold I., et al. Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am. Heart J. 2004, 147(6):1117-1124.
10. Jamshidi Y., Flavell D.M., Hawe E., MacCallum P.K., Meade T.W., Humphries S.E. Genetic determinants of the response to benzafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 2002, 163:183-192.
11. Kirkendall W.M., Feianleib M., Freis E.D., Mark A.L. Recommendation for human blood pressure determination of by sphygmomanometers. Circulation 1980, 62:1146.
12. Kisfali P., et al. Triglyceride level affecting shared susceptibility genes in metabolic syndrome and coronary artery disease. Curr. Med. Chem. 2010, 17(30):3533-3541.
13. Kontula K., Aalto-Setälä K., Kuusi T., Hämäläinen L., Syvänen A.C. Apolipoprotein E polymorphism determined by restriction enzyme analysis of DNA amplified by polymerase chain reaction: convenient alternative to phenotyping by isoelectric focusing. Clin. Chem. 1990, 36(12):2087-2092.
14. Kota B.P., Huang T.H.W., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 2005, 51:85-94.
15. Lahoz C., et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154(3):529-537.
16. Marx N., Schönbeck U., Lazar M.A., Libby P., Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 1998, 83:1097-1103.
17. National Cholesterol Education Program Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89(3):1333-1445.
18. Peng D.Q., Zao S.P., Nie S., Li J. Gene-gene interaction of PPARγ and ApoE affects coronary heart disease risk. Int. J. Cardiol. 2003, 92(2-3):257-263.
19. Plourde M., Vohl M.C., Vandal M., Couture P., Lemieux S., Cunnane S.C. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br. J. Nutr. 2009, 102(8):1121-1124.
20. Ricote M., et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7614-7619.
21. Robitaille J., et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 2004, 49(9):482-489.
22. Silbernagel G., et al. The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp. Clin. Endocrinol. Diab. 2009, 117(3):113-118.
23. Tai E.S., et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 2002, 22(5):805-810.
24. Tai E.S., et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006, 187(1):153-160.
25. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Committee Report). Diabetes Care 1998, 21(Suppl. 1):S5-S19.
26. Vohl M.C., et al. Molecular scanning of the human PPAR a gene: association of the L162V mutation with hyperapobetalipoproteinemia. J. Lipid Res. 2000, 41:945-952.
27. Wan J., et al. PPARg gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc. Diabetol. 2010, 9:13.
28. Wang X.L., Oosterhof J., Duarte N. Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease. Cardiovasc. Res. 1999, 44(3):588-594.
29. Yilmaz-Aydogan H., et al. Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without type 2 diabetes. Mol. Cell. Biochem. 2011, 358(1-2):355-363.
30. Yilmaz-Aydogan H., et al. Investigation of polymorphic variants of PPARD and APOE genes in Turkish coronary heart disease patients. DNA Cell Biol. 2012, 31(5):867-875.